American Pharmaceutical Partners To Report 2003 Second Quarter Financial Results and Host Conference Call on July 24.Business Editors SCHAUMBURG, Ill.--(BUSINESS WIRE)--July 9, 2003 Thursday, July 24, 2003, at 9:00 a.m. Eastern (6:00 a.m. Pacific) American Pharmaceutical Partners, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APPX APPX Appendix APPX Application eXcellence (4GL software development tool) ) said that on Thursday, July 24, 2003, the company will release its financial results for its 2003 second quarter. The company also said that Patrick Soon-Shiong, M.D., the company's Chairman, President and Chief Executive Officer, Nicole Williams, Chief Financial Officer, Derek Brown, Co-Chief Operating Officer, and Jeffrey Yordon, Co- Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , will host an investor conference call that same day at 9:00 a.m. Eastern (6:00 a.m. Pacific) to review the company's financial results and operations. The conference call will be available to interested parties through a live audio Internet broadcast at www.appdrugs.com and www.companyboardroom.com. The call will be archived and accessible at both sites for one year. About American Pharmaceutical Partners, Inc. American Pharmaceutical Partners, Inc. (APP) is a specialty drug company that develops, manufactures and markets injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. The company is one of the largest producers of injectable pharmaceuticals, with more than 130 generic products in more than 350 dosages and formulations. APP has acquired the exclusive North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. rights to manufacture and market a proprietary injectable oncology product, currently in phase III clinical trials for metastic breast cancer, which has been completely enrolled and for which the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has granted "Fast Track" product status. ABI-007 is also being studied in a variety of other cancers. For more information, visit APP's website at www.appdrugs.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion